Moderna, mRNA and bird flu

Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...
SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Moderna stock surged Wednesday after Oracle Chairman Larry Ellison praised the potential of AI in developing medicines.
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...